Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib + Everolimus + Lenvatinib in Advanced Solid Tumors
NCT04803318Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2021
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib, everolimus and lenvatinib in solid tumor and hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Treatment-Emergent Adverse Events at 36 months and Response to treatment at 36 months. Started Jan 2021; status: recruiting.
02
Drugs
trametinibeverolimuslenvatinib
03
Conditions
solid tumorhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04803318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04803318.